Neurofilament light chain as a potential biomarker for monitoring neurodegeneration in X-linked adrenoleukodystrophy.
Isabelle WeinhoferPaulus RommerBettina ZierfussPatrick AltmannMartha FoianiAmanda HeslegraveHenrik ZetterbergAndreas GleissPatricia L MusolinoYi GongSonja Forss-PetterThomas BergerFlorian EichlerPatrick AubourgWolfgang KöhlerJohannes BergerPublished in: Nature communications (2021)
X-linked adrenoleukodystrophy (X-ALD), the most frequent monogenetic disorder of brain white matter, is highly variable, ranging from slowly progressive adrenomyeloneuropathy (AMN) to life-threatening inflammatory brain demyelination (CALD). In this study involving 94 X-ALD patients and 55 controls, we tested whether plasma/serum neurofilament light chain protein (NfL) constitutes an early distinguishing biomarker. In AMN, we found moderately elevated NfL with increased levels reflecting higher grading of myelopathy-related disability. Intriguingly, NfL was a significant predictor to discriminate non-converting AMN from cohorts later developing CALD. In CALD, markedly amplified NfL levels reflected brain lesion severity. In rare cases, atypically low NfL revealed a previously unrecognized smoldering CALD disease course with slowly progressive myelin destruction. Upon halt of brain demyelination by hematopoietic stem cell transplantation, NfL gradually normalized. Together, our study reveals that blood NfL reflects inflammatory activity and progression in CALD patients, thus constituting a potential surrogate biomarker that may facilitate clinical decisions and therapeutic development.
Keyphrases
- white matter
- multiple sclerosis
- end stage renal disease
- resting state
- ejection fraction
- newly diagnosed
- chronic kidney disease
- prognostic factors
- oxidative stress
- functional connectivity
- peritoneal dialysis
- patient reported outcomes
- risk assessment
- brain injury
- cerebral ischemia
- single cell
- blood brain barrier
- protein protein
- drug induced